Cost-effectiveness evaluation for pricing medicines and devices: a new value-based price adjustment system in Japan

18 May 2020 - In Japan, a new cost-effectiveness evaluation system for medicine and medical device pricing was employed in April ...

Read more →

Valuing and pricing remdesivir: should drug makers get paid for helping us get back to work?

20 May 2020 - On April 29, the National Institutes of Health announced that in a placebo-controlled trial of patients with ...

Read more →

Putting a dollar value on life? Governments already do

11 May 2020 - Trade-offs are routine in health policy, and the math and analysis underlying them have been around for ...

Read more →

COVID-19 raises questions about the value of personalised medicine

8 May 2020 - A group of medical dissenters argues that tailoring treatment to the genetic profiles of individuals, a longstanding ...

Read more →

How are incremental cost effectiveness, contextual considerations, and other benefits viewed in health technology assessment recommendations in the United States?

 7 May 2020 - This study reviews ICER assessments to explore the relationship between incremental cost-effectiveness, other benefits, and contextual factors ...

Read more →

Cost‐effectiveness and financial risks associated with immune checkpoint inhibitor therapy

1 May 2020 - The reimbursement of the immune checkpoint inhibitors is challenging.  ...

Read more →

Swiss study sees no link between cancer drug prices and patient benefits

1 May 2020 - New research from the University of Zurich renews calls for more transparency in the way drug ...

Read more →

Using QALYs versus DALYs to measure cost effectiveness: how much does it matter?

30 April 2020 - Quality-adjusted life-years and disability-adjusted life-years are commonly used in cost effectiveness analysis to measure health benefits. Gent ...

Read more →

Getting value right: the case for indirect benefits

19 March 2020 - According to the most recent estimates from the Centers for Medicare and Medicaid Services Office of the ...

Read more →

Inappropriate use of progression-free survival in cancer drug approvals

10 March 2020 - New drugs should be judged on overall survival or quality of life, preferably both. ...

Read more →

New brand-name HIV prevention pill not worth the added cost

10 March 2020 - A cheaper HIV prevention pill is going on sale soon in the U.S., but the price ...

Read more →

ICER finalises 2020 updates to methods and public meeting procedures for value assessment framework

31 January 2020 - Reflecting experience with previous framework, benchmarking with other HTA groups, and input from more than 100 organisations ...

Read more →

Why cancelling your private health insurance could have unintended consequences

20 January 2020 - Nick Maconachie and Anna Dimeas have very different views on private health cover. ...

Read more →

Pricing of pharmaceuticals is becoming a major challenge for health systems

13 January 2020 - Manufacturers using their market power to maximise profits results in prices that are unjustifiable and unaffordable. ...

Read more →

Defining the concept of fair pricing for medicines

13 January 2020 - Suerie Moon and colleagues consider what makes a fair price for both buyers and sellers. ...

Read more →